NSE / BSEHealthcare
β‚Ή964.70-13.55-1.39%
P/E0.0Mkt Capβ‚Ή16.58 K CrEV/EBITDA140.4

JUBILANT PHARMOVA LIMITED

P/E0.0Mkt Capβ‚Ή16.58 K CrEV/EBITDA140.4
Company Profile

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
β€”
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 17.81% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+13.1%); Feb the lowest (-11.2%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-8.7%Negative MonthJan 2026: -8.74%-11.7%Negative MonthFeb 2026: -11.67%-5.8%Negative MonthMar 2026: -5.76%+13.5%Positive MonthApr 2026: +13.51%+7.2%Positive MonthMay 2026: +7.21%-2.2%Negative MonthJun 2026: -2.20%-0.7%*Neutral MonthJul 2026: -0.73%β€”β€”β€”β€”β€”
2025-12.0%Negative MonthJan 2025: -11.95%-7.2%Negative MonthFeb 2025: -7.21%-1.1%Neutral MonthMar 2025: -1.08%+0.5%Neutral MonthApr 2025: +0.52%+30.7%Positive MonthMay 2025: +30.65%+3.1%Positive MonthJun 2025: +3.14%-1.3%Neutral MonthJul 2025: -1.33%-14.6%Negative MonthAug 2025: -14.55%+5.8%Positive MonthSep 2025: +5.80%+1.8%Neutral MonthOct 2025: +1.76%-0.5%Neutral MonthNov 2025: -0.55%-1.5%Neutral MonthDec 2025: -1.54%
2024+4.7%Positive MonthJan 2024: +4.71%-0.7%Neutral MonthFeb 2024: -0.74%+0.2%Neutral MonthMar 2024: +0.23%+18.4%Positive MonthApr 2024: +18.39%+1.8%Neutral MonthMay 2024: +1.83%+7.8%Positive MonthJun 2024: +7.83%+4.7%Positive MonthJul 2024: +4.74%+18.9%Positive MonthAug 2024: +18.90%+25.2%Positive MonthSep 2024: +25.16%+5.2%Positive MonthOct 2024: +5.25%+1.8%Neutral MonthNov 2024: +1.77%-10.5%Negative MonthDec 2024: -10.48%
2023-6.2%Negative MonthJan 2023: -6.25%-12.9%Negative MonthFeb 2023: -12.91%-9.0%Negative MonthMar 2023: -8.96%+11.6%Positive MonthApr 2023: +11.57%+5.9%Positive MonthMay 2023: +5.94%+20.9%Positive MonthJun 2023: +20.90%-5.4%Negative MonthJul 2023: -5.35%+24.2%Positive MonthAug 2023: +24.16%-7.2%Negative MonthSep 2023: -7.21%-13.9%Negative MonthOct 2023: -13.88%+14.8%Positive MonthNov 2023: +14.81%+26.9%Positive MonthDec 2023: +26.93%
2022-11.5%Negative MonthJan 2022: -11.46%-23.5%Negative MonthFeb 2022: -23.52%-2.4%Negative MonthMar 2022: -2.43%+21.8%Positive MonthApr 2022: +21.75%-18.5%Negative MonthMay 2022: -18.51%-10.8%Negative MonthJun 2022: -10.80%+5.4%Positive MonthJul 2022: +5.42%-3.1%Negative MonthAug 2022: -3.14%-4.3%Negative MonthSep 2022: -4.27%+9.6%Positive MonthOct 2022: +9.61%+6.4%Positive MonthNov 2022: +6.36%-4.0%Negative MonthDec 2022: -4.03%
2021β€”β€”β€”β€”β€”-16.6%Negative MonthJun 2021: -16.61%-6.2%Negative MonthJul 2021: -6.24%-3.4%Negative MonthAug 2021: -3.37%-5.9%Negative MonthSep 2021: -5.94%-4.6%Negative MonthOct 2021: -4.59%-1.7%Neutral MonthNov 2021: -1.72%+0.4%Neutral MonthDec 2021: +0.37%
AvgΒ±SD-6.7%Β±6.1%-11.2%Β±7.5%-3.6%Β±3.3%+13.1%Β±7.3%+5.4%Β±15.7%+0.4%Β±12.3%-0.6%Β±4.5%+4.4%Β±14.7%+2.7%Β±12.1%-0.4%Β±8.2%+4.1%Β±6.0%+2.3%Β±12.9%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.898x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή746.00 Crβ–Ό 5.0%
EBITDA Growthβ€”
Net Profitβ‚Ή19.00 Crβ–Ό 40.6%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 196.0%
Revenue CAGR 5Y-24.2%
EBITDA CAGR 5Y-26.1%
Net Profit CAGR 5Y-36.9%
NP Growth 1Y-40.6%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή746.00 Crβ€”β‚Ή19.00 Crβ€”β€”0.8%-5.0%-40.6%
Mar 2024β‚Ή785.00 Crβ€”β‚Ή32.00 Crβ€”β€”1.3%-3.1%-36.0%
Mar 2023β‚Ή810.00 Crβ€”β‚Ή50.00 Crβ€”β€”2.1%11.6%-37.5%
Mar 2022β‚Ή726.00 Crβ€”β‚Ή80.00 Crβ€”β€”3.3%-73.2%-62.6%
Mar 2021β‚Ή2.71 K Crβ€”β‚Ή214.00 Crβ€”β€”16.7%-13.7%-33.3%
Mar 2020β‚Ή3.14 K Crβ€”β‚Ή321.00 Crβ€”β€”12.3%-8.7%116.9%
Mar 2019β‚Ή3.44 K Crβ€”β‚Ή148.00 Crβ€”β€”6.3%4.0%-43.7%
Mar 2018β‚Ή3.31 K Crβ€”β‚Ή263.00 Crβ€”β€”11.7%32.7%232.9%
Mar 2017β‚Ή2.49 K Crβ€”β‚Ή79.00 Crβ€”β€”3.9%-6.2%8.2%
Mar 2016β‚Ή2.66 K Crβ€”β‚Ή73.00 Crβ€”β€”3.6%-16.3%-64.4%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales3,6663,1722,6562,4913,3063,4393,1402,710726810785746383
Total Expenses3,0762,8902,3442,1732,7653,1122,7652,282719807767714339
EBIT / Operating Profit59028231231854132637542763183244
OPM %16%9%12%13%16%9%12%16%1%0%2%4%12%
Other Income-19830562524572168481261381028876
Finance Costs2852332011741351291361021118303016
Depreciation & Amortisation175107878183861071003743485318
Profit Before Tax-68246861153681832992738579423886
Tax %-101%17%16%31%28%20%-7%21%5%37%24%49%-
Net Profit / PAT120573792631483212148050321918
EPS (β‚Ή)0.0512.884.584.9716.549.2720.1613.465.053.131.981.211.14
Dividend Payout %5,652%23%65%60%18%49%25%37%99%159%252%414%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
JUBILANT PHARMOVA LIMITEDthis co.β‚Ή16.58 K Crβ‚Ή746.00 Cr0.007.38140.36-5.0%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of JUBILANT PHARMOVA LIMITED and the metrics that matter.

Browse the full Equiscale Academy